Dulaglutide is one of these long-acting GLP1 receptor agonists administered as a once-weekly subcutaneous injection approved for the treatment of adults with T2DM in 2014 and can be used as a monotherapy or in addition to an oral hypoglycemic or insulin therapy [5, 8, 10]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.